Morse M A, Lyerly H K
Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710, USA.
Ann Surg Oncol. 1999 Mar;6(2):218-23. doi: 10.1007/s10434-999-0218-x.
Because of the high relapse rate of resected gastrointestinal malignancies and the modest responses of metastatic disease to currently available therapies, biologic agents that harness host-tumor immunologic interactions have received increased attention. Based on promising preclinical data, current clinical trials in cellular and biologic therapies are evaluating the safety and efficacy of passive immunotherapy with tumor-reactive lymphocytes activated ex vivo and active immunotherapy with peptide, viral vector, and cellular vaccines. This review will describe the background, rationale, and experimental approach of these clinical trials. Although equally promising, antibodies, gene therapies, and antiangiogenic strategies will not be discussed.
由于切除的胃肠道恶性肿瘤复发率高，且转移性疾病对现有疗法反应有限，利用宿主与肿瘤免疫相互作用的生物制剂受到了更多关注。基于有前景的临床前数据，目前细胞和生物疗法的临床试验正在评估体外激活的肿瘤反应性淋巴细胞被动免疫疗法以及肽、病毒载体和细胞疫苗主动免疫疗法的安全性和有效性。本综述将描述这些临床试验的背景、原理和实验方法。尽管抗体、基因疗法和抗血管生成策略同样具有前景，但本文将不予讨论。
